Advertisement

CME

, Volume 15, Issue 10, pp 59–66 | Cite as

Welche Patienten mit chronisch aktiver CED benötigen eine Biologikatherapie?

Chronisch entzündliche Darmerkrankungen
  • Max Reinshagen
CME Fortbildung
  • 45 Downloads

Zusammenfassung

In den letzten Jahren wurden eine Reihe innovativer Substanzen zur wirksamen Therapie chronisch entzündlicher Darmerkrankungen entwickelt und zugelassen. In der Praxis stellt sich häufig die Frage, welcher Patient mit Morbus Crohn oder Colitis ulcerosa in Deutschland wirklich einen komplexen chronisch aktiven Krankheitsverlauf hat und deshalb frühzeitig immunmodulatorisch behandelt werden sollte.

Schlüsselwörter

Morbus Crohn Colitis ulcerosa Biologikatherapie 

Literatur

  1. 1.
    Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH, et al. Clinical course in Crohn’s disease: results of a five-year population-based follow-up study (the IBSEN study). Scandinavian journal of gastroenterology. 2007;42(5):602–10.CrossRefGoogle Scholar
  2. 2.
    Solberg IC, Lygren I, Jahnsen J, Aadland E, Hoie O, Cvancarova M, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scandinavian journal of gastroenterology. 2009;44(4):431–40.CrossRefGoogle Scholar
  3. 3.
    Faubion WA, Jr., Loftus EV, Jr., Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121(2):255–60.CrossRefGoogle Scholar
  4. 4.
    D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet (London, England). 2008;371(9613):660–7.CrossRefGoogle Scholar
  5. 5.
    Preiss JC, Bokemeyer B, Buhr HJ, Dignass A, Hauser W, Hartmann F, et al. Diagnostik und Therapie des Morbus Crohn - 2014 Zeitschrift fur Gastroenterologie. 2014;52(12):1431–84.Google Scholar
  6. 6.
    Dignass A, Preiss JC, Aust DE, Autschbach F, Ballauff A, Barretton G, et al. Aktualisierte Leitlinie zur Diagnostik und Therapie der Colitis ulcerosa 2011 Ergebnisse einer Evidenzbasierten Konsensuskonferenz. Zeitschrift fur Gastroenterologie. 2011;49(9):1276–341.CrossRefGoogle Scholar
  7. 7.
    West NR, Hegazy AN, Owens BMJ, Bullers SJ, Linggi B, Buonocore S, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23(5):579–89.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn’s disease. Gastroenterology. 2006;130(3):650–6.CrossRefGoogle Scholar
  9. 9.
    Pariente B, Cosnes J, Danese S et al. Development of the Crohn’s disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011;17:1415–1422CrossRefGoogle Scholar
  10. 10.
    Casellas F, Herrera-de Guise C, Robles V, Navarro E, Borruel N. Patient preferences for inflammatory bowel disease treatment objectives. Dig Liver Dis. 2017;49(2):152–6.CrossRefGoogle Scholar
  11. 11.
    Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet (London, England). 2002;359(9317):1541–9.CrossRefGoogle Scholar
  12. 12.
    Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.CrossRefGoogle Scholar
  13. 13.
    Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. Journal of Crohn’s & colitis. 2013;7(3):213–21.CrossRefGoogle Scholar
  14. 14.
    Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol. 2016;7(4):289–300.CrossRefGoogle Scholar
  15. 15.
    Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Alimentary pharmacology & therapeutics. 2017;46(11-12):1037–53.CrossRefGoogle Scholar
  16. 16.
    Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vanasek T, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet (London, England). 2017.CrossRefGoogle Scholar
  17. 17.
    Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D’Haens G, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. Journal of Crohn’s & colitis. 2009;3(2):47–91.CrossRefGoogle Scholar
  18. 18.
    Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. The New England journal of medicine. 2013;369(8):711–21.CrossRefGoogle Scholar
  19. 19.
    Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. The New England journal of medicine. 2013;369(8):699–710.CrossRefGoogle Scholar
  20. 20.
    Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. The New England journal of medicine. 2012;367(16):1519–28.CrossRefGoogle Scholar
  21. 21.
    Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet (London, England). 2017;389(10066):266–75.CrossRefGoogle Scholar
  22. 22.
    Feagan BG, Sandborn WJ, D’Haens G, Panes J, Kaser A, Ferrante M, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet (London, England). 2017;389(10080):1699–709.CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Medizinische Klinik I, Klinik für Magen- und DarmerkrankungenStädtisches Klinikum BraunschweigBraunschweigDeutschland

Personalised recommendations